|
|
|
| Clinical effect of Ivabradine Tablets combined with Atorvastatin Calcium Tablets in the treatment of patients with carotid atherosclerosis |
| JIANG Ren-gui ZENG Xiang-hui ZHAO Li-li ZHANG Bi-long |
| Department of Cardiology,Ganzhou Municipal Hospital,Jiangxi Province,Ganzhou 341000,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Ivabradine Tablets combined with Atorvastatin Calcium Tablets in the treatment of patients with carotid atherosclerosis.Methods A total of 84 patients with carotid atherosclerosis admitted to Ganzhou Municipal Hospital from June 2018 to March 2020 were selected as the research objects,and were divided into control group(n=40)and observation group(n=44).The control group was treated with Atorvastatin Calcium Tablets,and the observation group was treated with Ivabradine Tablets combined with Atorvastatin Calcium Tablets.The changes in blood lipid metabolism,inflammation and oxidative stress levels were compared between the two groups.Results After six months of treatment,the total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterin(LDL-C),high density lipoprotein cholesterol(HDL-C)concentration,high sensitivity C-reactive protein(hs-CRP),oxidized low density lipoprotein(ox-LDL)and oxidative stress marker malondialdehyde(MDA)levels of the observation group were lower than those of the control group,and the superoxide dismutase(SOD)level was higher than that of the control group,the differences were statistically significant(P＜0.05).After half a year of treatment,the medial intima thickness(IMT)in the observation group was lower than that of the control group,with statistical difference(P＜0.05).Conclusion Ivabradine Tablets combined with Atorvastatin Calcium Tablets has a prominent effect on blood lipid metabolism,inflammation and oxidative stress in patients with carotid atherosclerosis.It obtains a significant antiatherosclerosis effect and is beneficial to the prevention of cardiovascular and cerebrovascular events.
|
|
|
|
|
|
| [1] |
纪利利，李美杰，姚丽娜，等.他汀类药物治疗急性脑梗死对患者颈动脉粥样硬化斑块及炎症反应的影响[J].现代中西医结合，2018，27（22）：2491-2494.
|
| [2] |
周汇文.他汀类药物对急性脑梗死病人颈动脉粥样硬化斑块及炎症反应的影响[J].中西医结合心脑血管病杂志，2018，16（4）：481-484.
|
| [3] |
高华，裴静，陈明，等.急性脑梗死病人血清胱抑素C 与颈动脉粥样硬化、脂蛋白的相关性分析[J].中西医结合心脑血管病杂志，2017，15（17）：2172-2174.
|
| [4] |
曾显明，董喜梅，冯辉.伊伐布雷定治疗慢性心力衰竭的疗效及其对患者血清GDF-15、sST2 水平的影响[J].海南医学，2019，3（1）：332-333.
|
| [5] |
Dominguez-Rodriguez A，Blanco-Palacios G，Abreu-Gonzalez P.Increased heart rate and atherosclerosis：potential implications of ivabradine therapy[J].World J Cardiol，2011，3（4）：101-104.
|
| [6] |
Skalidis EI，Hamilos MI，Chlouverakis G，et al.Ivabradine improves coronary flow reserve in patients with stable coronary artery disease[J].Atherosclerosis，2011，215（1）：160-165.
|
| [7] |
钟文津，杨炳昂，景香香，等.超声检查评价阿托伐他汀联合氯吡格雷对急性脑梗死患者颈动脉粥样硬化斑块的影响[J].中国实验诊断学，2017，21（9）：1547-1550.
|
| [8] |
李加林，唐毓启，胡志勇.不同剂量阿托伐他汀治疗冠心病的疗效及对血清细胞因子和颈动脉粥样硬化斑块的影响[J].河北医药，2017，20（21）：320-321.
|
| [9] |
张丽，巩晓英，王继恒.阿托伐他汀联合氯吡格雷及拜阿司匹林对进展性脑梗死患者颈动脉粥样硬化的疗效评价[J].贵州医药，2019，43（12）：1945-1947.
|
| [10] |
时珊珊.伊伐布雷定在心血管疾病中的临床研究进展[J].中国循环杂志，2015，6（30）：613-614.
|
| [11] |
Thorup L，Simonsen U，Grimm D，et al.Ivabradine：Current and Future Treatment of Heart Failure[J].Basic Clin Pharmacol Toxicol，2017，121（2）：89-97.
|
| [12] |
孙志明.伊伐布雷定治疗窄QRS 心动过速的临床疗效[J].实用心脑肺血管病杂志，2018，26（10）：103-106.
|
| [13] |
李传荣，姜东炬.伊伐布雷定在心血管疾病中的研究进展[J].心血管病学进展，2019，40（1）：149-151.
|
| [14] |
Luong L，Duckles H，Schenkel T，et al.Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflammatory mechanisms in arteries[J].Thromb Haemost，2016，116（1）：181-190.
|
| [15] |
汪海燕，王喆，李慧芳，等.益心舒片联合伊伐布雷定治疗慢性稳定型心绞痛的临床研究[J].现代药物与临床，2019，34（3）：648-651.
|
| [16] |
陆瑶华，沈卫华.伊伐布雷定联合左西孟旦对老年慢性心力衰竭患者心室重构的影响[J].中国医药导报,2020，17（27）：123-126，130.
|
|
|
|
